Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
---|---|---|---|---|---|
Christopher Anzalone | Chief Executive Officer, Director | $75.9M | -$1.03M | -1.34% | Feb 7, 2025 |
Patrick O'Brien | COO and General Counsel | $10.4M | -$736K | -6.62% | Jan 4, 2025 |
Kenneth Myszkowski | Chief Financial Officer | $8.97M | -$2.3M | -20.4% | Jan 4, 2025 |
Javier San | Chief Medical Officer | $7.42M | Jan 4, 2024 | ||
James Hamilton | Chief Discovery/Trans Medicine | $5.47M | -$817K | -13% | Jan 4, 2025 |
James Hassard | Chief Commercial Officer | $3.95M | Jun 22, 2021 | ||
Tracie Oliver | Chief Commercial Officer | $3.21M | -$237K | -6.88% | Jul 2, 2024 |
Michael Perry | Director | $3.02M | Dec 18, 2024 | ||
Douglas B. Given | Director | $2.74M | -$122K | -4.25% | Dec 16, 2024 |
Mauro Ferrari | Director | $1.78M | Dec 18, 2024 | ||
William D. Waddill | Director | $1.31M | -$165K | -11.1% | Dec 18, 2024 |
Marianne De Backer | Director | $1.17M | Jan 10, 2023 | ||
Hongbo Lu | Director | $1.08M | +$145K | +15.5% | Dec 18, 2024 |
Victoria Vakiener | Director | $872K | -$239K | -21.5% | Dec 18, 2024 |
Douglas S. Ingram | Director | $771K | Feb 6, 2025 | ||
Adeoye Olukotun | Director | $751K | -$77.1K | -9.31% | Jan 23, 2025 |
Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
---|